摘要
目的探讨正电子发射计算机断层显像-计算机断层摄影术(PET-CT)的最大标化摄取值(SUVmax)水平与弥漫大B细胞淋巴瘤(DLBCL)患者临床病理参数及预后指标的关系。方法根据治疗前患者PET-CT的SUVmax水平高低,将57例初治的DLBCL患者分为SUVmax<10组和SUVmax≥10组,回顾性分析2组患者治疗前PET-CT的SUVmax与分期、乳酸脱氢酶(LDH)、Ki-67、CD5、双(三)表达或打击、治疗4或6周期的有效率及2 a疾病无进展生存率等多个临床病理参数及预后相关因素进行关联性分析。结果治疗前PET-CT的SUVmax与分期、LDH、CD5有关(P均<0.05)。经过4或6周期治疗,SUVmax<10组和SUVmax≥10组的有效率和疾病控制率比较差异均无统计学意义(P均>0.05)。SUVmax<10组和SUVmax≥10组的2 a疾病无进展生存率分别为91.7%和68.3%,差异有统计学意义(P<0.05)。结论治疗前PET-CT的SUVmax与分期、LDH、CD5有关,且治疗前SUVmax与DLBCL的疾病无进展生存期有关,治疗前PET-CT的SUVmax可以作为DLBCL的预后分析的指标之一。
Objective To investigate the correlation between mmxinmnl standard uptake value （SUVmmx） of pos- itron emission tomography-computed tomography （PET-CT） in patients of diffuse large B cell lymphoma （DLBCL）. Methods Fifty-seven patients with DLBCL without any previous treatments were enrolled in this project. Accord- ing to the SUVmax in PET-CT, the patients were divided into two groups （the SUVmax 〈 10 group and the SUV- max ≥ 10 group）. Statistical analyses were performed to evaluate the correlations between the elinieolpathologieal characteristics including stage, lactic dehydrogenase （LDH） level, Ki-67, CD5, double （three） the expression or hit, response rate and 2 years progress free survival rates after four or six cycles of treatment as well as the predic- tive value between the two groups. Results The results showed there were statistical differences between SUVmax of PET-CT before treatment and stage, LDH before treatment and CD5 （P 〈 0.05）. It was also found that there were any significant differences between the SUVmax 〈 10 group and the SUVmax≥ 10 group in the response rate and the disease control rate （P 〉 0.05 ）. However, it was found that there was a statistically significant difference between the SUVmax 〈 10 group and the SUVmax1〉 10 group in the 2 years progress free survival rates （P 〈 0.05 ）. Conclusion SUVmax of PET-CT before treatment was associated with stage, LDH level before treatment and CD5 expression status. The high level of SUVmax in PET-CT before treatment can also be served as a poor pre- dictive factor in DLBCL.
作者
杨刚
李亚青
柳喜洋
张超
张蕾
YANG Gang;LI Yaqing;LIU Xiyang;ZHANG Chao;ZHANG Lei(Department of Oncology, the First Affiliated Hospital of Zhengzhou University , Zhengzhou 450052 , Chin)
出处
《肿瘤基础与临床》
2018年第2期122-125,共4页
journal of basic and clinical oncology
